|1.||Reinwarth, Michael: 1 article (08/2015)|
|2.||Avrutina, Olga: 1 article (08/2015)|
|3.||Valldorf, Bernhard: 1 article (08/2015)|
|4.||Dickgießer, Stephan: 1 article (08/2015)|
|5.||Schmoldt, Hans-Ulrich: 1 article (08/2015)|
|6.||Maaß, Franziska: 1 article (08/2015)|
|7.||Kolmar, Harald: 1 article (08/2015)|
|8.||Wüstehube-Lausch, Joycelyn: 1 article (08/2015)|
|9.||Sahin, Ugur: 1 article (08/2015)|
|10.||Daneschdar, Matin: 1 article (08/2015)|
|1.||Melanoma (Melanoma, Malignant)
08/01/2015 - "In this study, we demonstrated that the cystine-knot peptide MCoTI-II, a trypsin inhibitor from Momordica cochinchinensis, can be engineered to bind to cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, that has emerged as a target for the treatment of metastatic melanoma. "
|2.||Prostatic Neoplasms (Prostate Cancer)
|3.||Breast Neoplasms (Breast Cancer)
01/01/2007 - "Cell uptake was examined for representatives of two cyclotide subfamilies; the first was MCoTI-II, a member of the trypsin inhibitor subfamily, which was internalized by a macrophage and breast cancer cell line and the second, the prototypic cyclotide kalata B1 from the Möbius subfamily, which remained extracellular. "
|3.||cytotoxic T-lymphocyte antigen 4